Drug Overview: Forteo

  • ID: 4533486
  • Report
  • 18 pages
  • Datamonitor Healthcare
1 of 3
Drug Overview

Forteo (teriparatide; Eli Lilly) is a recombinant N-terminal fragment (amino acids 1-34) of human parathyroid hormone (PTH). Endogenous PTH plays a central role in the regulation of calcium and phosphate metabolism in mammals and acts to regulate bone remodeling. PTH is a direct anabolic agent in bone tissue and acts to stimulate the formation of new bone by activating osteoblasts. The 34 N-terminal amino acids contained in Forteo are the biologically active region of PTH, and Forteo has the same biological functions. Forteo acts to increase skeletal mass and bone strength and is not detrimental to the skeleton, unlike a continuous excess of endogenous PTH.
Note: Product cover images may vary from those shown
2 of 3
OVERVIEW
Drug Overview
Product Profiles
Forteo: Osteoporosis

List of Figures
Figure 1: Forteo for osteoporosis - SWOT analysis
Figure 2: Drug assessment summary of Forteo for osteoporosis
Figure 3: Drug assessment summary of Forteo for osteoporosis

List of Tables
Table 1: Forteo drug profile
Table 2: Forteo pivotal trial data in osteoporosis
Table 3: Forteo late-phase trial data in osteoporosis
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll